We unlock the potential of existing medicines by applying them in a smart, targeted way.

LinXis is the world's first and only fibrobody-drug conjugate company

We are the first to use targeted delivery methods to combat fibrosis - a condition that afflicts millions of people worldwide. Our approach towards fibrosis is not only about extending and saving lives, but also about improving quality of life for those suffering fibrotic disease. Many fibrosis patients are young; our aim is to give them the chance to lead a healthy, happy life.

Linking medicines to in-house developed Fibrobodies™

We can selectively deliver proven medicines to fibrotic tissue, in order to selectively de-activate fibrosis-mediating cells.

Our solution harnesses the power of existing medicines by coupling them to in-house developed Fibrobodies™ using our own ‘plug and play’ conjugation technology.

Our Fibrobodies^TM and conjugation technology are protected by several patent applications.

Image: graphical rendering of the actual spatial structure of a Fibrobody

We are tackling a growing health concern

Research points to long-term growth in a multitude of fibrotic illnesses.

Liver Fibrosis

In the US alone, almost five million people are living with chronic liver disease

Kidney Fibrosis

Kidney fibrosis affects as many as 50 million people in the EU and USA alone

No treatment options

Other than transplant or the removal of the affected organs, there are no curative treatment options for advanced fibrosis

Increased Mortality

UK deaths due to liver disease have risen by 400% since 1970 (britishlivertrust.org.uk)

Growing Impact

Modern Western lifestyle will cause a rise of fibrotic disease within years

COVID-19

Lung fibrosis may develop in more than half of severe COVID-19 patients

Long term growth

The potential to diversify and maximize impact

We pursue sub-approaches for multiple fibrotic diseases by targeting Fibrobodies to liver, lung, kidney or gut.

Liver fibrosis

Kidney fibrosis

Lung fibrosis

Fibrosis of the gut

We are experienced pioneers, ready to take the next step

With an experienced, close-knit scientific team, we are ready to take our solution to the next level. We hold all required knowledge and expertise under one roof - LinXis’ specialists self-manage the entire pharmaceutical development cycle – from Fibrobody-drug conjugate design to preclinical- and clinical development.

Bart Nijmeijer PhD

Chief Executive Officer

Prof. Guus van Dongen

Chief Scientific Officer

Samuel Oudkerk

Chief Business & Financial Officer

Contact us

Join our mission. Join us.

LinXis is always open to possibilities that could support our company and our pipeline. Do not hesitate to reach out to us at:

LinXis B.V.

Cronenburg 75
1081GM Amsterdam
The Netherlands

Join our mission. Join us.

LinXis is always open to possibilities that could support our company and our pipeline. Do not hesitate to reach out to us at:

LinXis and the Amsterdam UMC Imaging Center

In the Imaging Center, state-of-the art imaging technologies are brought together with worldwide scientific and medical expertise - and now also our Research and Discovery Staff.